References
- Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–732.
- Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035.
- U.S. Preventive Services Task Force. Draft recommendation statement: prostate cancer: screening. April 2017. [Internet]; Available from: https://www.uspreventiveservicestaskforce.org/Page/Docu-ment/RecommendationStatementDraft/prostate-cancer-screening1
- Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
- Carter HB, Albertsen C, Barry MJ, et al. American Urological Association. Early detection of prostate cancer: AUA guidelines. 2017. [Internet]; Available from: https://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015
- Mottet N, Bellmunt J, Briers E, et al. European Association of Urology. Guidelines on prostate cancer. 2017. [Internet]; Available from: http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf
- The Swedish National Board of Health and Welfare. Nationella Screeningprogram. 2017. [Internet]; Available from: http://www.socialstyrelsen.se/riktlinjer/nationellascreeningprogram/prostatacancer-screeningmedpsa
- Nordström T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63:419–425.
- Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314:2054–2061.
- Kilpeläinen TP, Talala K, Raitanen J, et al. Prostate cancer and socioeconomic status in the Finnish Randomized Study of Screening for Prostate Cancer. Am J Epidemiol. 2016. Available from: https://doi-org.ezproxy.ub.gu.se/10.1093/aje/kww084 [Epub ahead of print]
- World Health Organization, International Agency for Research on Cancer (IARC). IARC Handbooks of cancer prevention, volume 10, cervix cancer screening. Lyon: IARC Press; 2005.
- World Health Organization, International Agency for Research on Cancer (IARC). IARC Handbooks of cancer prevention, volume 7, breast cancer screening. Lyon: IARC Press; 2002.
- Palencia L, Espelt A, Rodriguez-Sanz M, et al. Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program. Int J Epidemiol. 2010;39:757–765.
- Spadea T, Bellini S, Kunst A, et al. The impact of interventions to improve attendance in female cancer screening among lower socioeconomic groups: a review. Prev Med. 2010;50:159–164.
- ERSPC website. 2017. [Internet]; Available from: http://www.esrpc.org/sweden
- Shavers VL. Measurement of socioeconomic status in health disparities research. J Natl Med Assoc. 2007;99:1013–1023.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
- Aalen O. Nonparametric inference for a family of counting processes. Ann Statist. 1978;6:701–726.
- Grenabo Bergdahl A, Holmberg E, Moss S, et al. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol. 2013;64:703–709.
- Arnsrud Godtman R, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68:354–360.
- Kilpeläinen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105:719–725.
- Roobol MJ, Kranse R, Bangma CH, et al. Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2013;64:530–539.
- Schröder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58:46–52.
- Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–132.
- Berglund A, Garmo H, Robinson D, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48:75–84.
- Rapiti E, Fioretta G, Schaffar R, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer. 2009;115:5556–5565.
- Morgan RM, Steele RJ, Nabi G, et al. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study. J Urol. 2013;190:1207–1212.
- Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. JCO. 2011;29:1736–1743.
- Guessous I, Cullati S, Fedewa SA, et al. Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. Prev Med. 2016;82:83–91.
- Carlsson S, Assel M, Ulmert D, et al. Screening for prostate cancer starting at age 50-54 years. A population-based cohort study. Eur Urol. 2017;71:46–52.